Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. The company is headquartered in Carlsbad, California and currently employs 54 full-time employees. The company went IPO on 2021-03-26. The company is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Follow-Up Questions
Who is the CEO of Design Therapeutics Inc?
Dr. Pratik Shah is the Chairman of the Board of Design Therapeutics Inc, joining the firm since 2017.
What is the price performance of DSGN stock?
The current price of DSGN is $6.13, it has decreased 1.92% in the last trading day.
What are the primary business themes or industries for Design Therapeutics Inc?
Design Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Design Therapeutics Inc market cap?
Design Therapeutics Inc's current market cap is $349.1M
Is Design Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for Design Therapeutics Inc, including 2 strong buy, 4 buy, 3 hold, 0 sell, and 2 strong sell
